In a large LEADER study involving 9340 patients with type 2 diabetes with higher cardiovascular risk, liraglutide reduced the risk of cardiovascular death, non-fatal MI, and non-fatal stroke by 13%. The risk of death was reduced by 15% and the risk of cardiovascular death was reduced by 22%. At the same time, liraglutide reduces HbA1c and body weight and reduces hypoglycemia. Liraglutide also became the second hypoglycemic agent to obtain evidence of a clear cardiovascular benefit after engliflozin.
Researchers at the University of Pennsylvania published a new study on the cardiovascular outcome of liraglutide on JAMA on August 2. The phase II study included a total of 300 patients with heart failure with or without diabetes for a period of 6 months. It was mainly investigated whether liraglutide could delay the death of patients, reduce hospitalization and improve clinical symptoms. The results showed that liraglutide did not provide significant benefits over placebo in the primary end points of death and hospitalization, with a rehospitalization rate of 38% and a mortality rate of 12%.
Kenneth Margulies, chief research officer of the study, said: “The main purpose of our research is to examine whether liraglutide can bring therapeutic benefits to patients with advanced heart failure, regardless of whether they are accompanied by diabetes. Now we have a relatively clear The answer is that liraglutide has no effect on the improvement of heart failure.”
Margulies believes that our study did not find that liraglutide is a safety issue and that patients should not discontinue liraglutide treatment, but as far as I am concerned, in the face of a heart failure patient who needs hypoglycemic therapy, I may try other hypoglycemic drugs.
Margulies’s team had previously performed a super-large retrospective, observational study that tracked data on 19,000 patients with diabetes in 2015 and found that liraglutide may have a role in preventing heart failure in people with diabetes. Unlike all patients in this observational study who had diabetes and did not have heart failure, this type of study published by JAMA is a prospective study. All patients are clearly diagnosed with heart failure and therefore have a higher risk of other complications.
David Lanfear, head of heart failure and transplant cardiology at Henry Ford Medical Group, said that taking into account previous findings and evidence from the latest research, liraglutide may be more beneficial in the early stages of heart failure.”
Liraglutide is the first GLP-1 receptor agonist to show cardiovascular benefits in cardiovascular outcome studies. Sanofifi’s just-accepted lixisenatide showed no increase in the risk of cardiovascular events in cardiovascular outcome studies, but it did not reduce the risk of cardiovascular events.
Luli-1, a weekly GLP-1 receptor agonist launched by Eli Lilly, was very popular in the market. Sales in the first half of 2016 were US$345 million, a 447.6% increase compared to the same period in 2015; evidence of cardiovascular benefit became Liraglutide is a great weapon for defending the market dominance of the GLP-1 market once a day.
Unfortunately, Express Scripts, the largest pharmacy welfare administration in the United States, has just released its 2017 drug purchase list. Victoza has been ruled out because of its unwillingness to provide higher discounts. Trulicity is retained. This incident will undoubtedly have a major impact on the GLP-1 market.